HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.